Learn how to provide customers leading API development services while advancing new compounds and increasingly complex chemistries, with an emphasis on manufacturability, yield optimization, safety, and efficacy.
The increasing complexity of the drugs currently in clinical development has created mounting pressure for companies hoping to overcome the challenges. Central to the pursuit is partnering with a CDMO with the capabilities and flexibility required to achieve the clinical milestones necessary for a drug’s ultimate commercial success.
As HPAPI molecules continue to play a growing role in new pharmaceutical products, biopharma companies will need access to flexible, sophisticated manufacturing assets to bring innovative products to market and to patients.
The increase in Breakthrough Therapy designations and other allowances for expedited regulatory review has led to ever more innovative drug products being developed under shortened timelines. But how can companies navigate today’s regulatory environment?